Philippe Généreux, a practicing Interventional Cardiologist and PhD candidate, has been honored with the TCT Young Investigator Award for his outstanding clinical skills and dedication to patient care. The award aims to encourage promising researchers in interventional cardiovascular medicine.
Dr. Barry D. Rutherford, MD, was awarded the TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award for his technical expertise and innovation in interventional cardiovascular medicine.
The radial approach has been shown to significantly reduce the incidence of major bleeding and access site complications compared to the femoral approach. In STEMI patients undergoing primary PCI within 12 hours, radial access was associated with a lower rate of major adverse cardiovascular events.
The RESPECT trial found that PFO closure significantly reduces the risk of recurrent ischemic strokes, with a clinical benefit of 46.6-72.7% compared to medical management alone. The study also showed low device-related risks and no device-related thrombus or embolization.
A new study presented at TCT 2012 confirms that intracoronary and intravenous use of abciximab during angioplasty yield similar results for heart damage and reperfusion injury in STEMI patients. The AIDA STEMI MRI sub-study examined various measures of heart damage using cardiac magnetic resonance imaging.
A large registry study found that patients with low levels of platelet inhibition after receiving a drug-eluting stent are at higher risk for blood clots and heart attacks. However, this responsiveness to clopidogrel was also linked to reduced bleeding complications.
The PC Trial found that catheter-based PFO closure using an investigational device did not decrease ischemic and bleeding events compared to standard medical therapy. Stroke risk was non-significantly reduced with device therapy, with a relative risk reduction of 37 percent.
A novel hydration protocol guided by left ventricular end-diastolic pressure reduced kidney damage by 59% in patients undergoing cardiac catheterization, according to the POSEIDON trial. The study found that this technique can be easily implemented and adapted for both inpatient and outpatient settings.
The MASTER trial found that mesh-covered stents demonstrated improved restoration of blood flow compared to bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty. The study showed a higher rate of ST-segment resolution with the new stent.
A study found that a nitinol stent performed better than balloon angioplasty alone in treating blockages of the popliteal artery, with higher one-year primary patency rates. The trial compared primary nitinol stent placement to angioplasty alone in patients with single obstructive lesions in the popliteal artery.
The TRILOGY ACS trial found prasugrel did not reduce cardiovascular events among patients managed medically for acute coronary syndrome. However, it was associated with lower rates of cardiovascular disease, heart attack, and stroke, but higher rates of bleeding when compared to clopidogrel.
The PARTNER Cohort B trial found TAVR to be beneficial for patients with severe aortic stenosis, with lower mortality rates and fewer cardiac deaths at three years compared to standard therapy. The study confirms the role of TAVR as the standard-of-care for symptomatic patients who are not surgical candidates.
The FAME 2 trial demonstrated that FFR-guided percutaneous coronary intervention (PCI) is a cost-effective strategy compared to medical therapy for patients with stable coronary artery disease (CAD). This approach improves clinical outcomes and quality of life, with a projected cost-effectiveness of $53,000 per quality-adjusted life year.
The ISAR-LEFT MAIN 2 trial presented at TCT 2012 found that second-generation drug-eluting stents are safe and effective for treating left main coronary artery lesions. The study showed similar clinical outcomes between zotarolimus-eluting and everolimus-eluting stents in patients with high-risk lesions.
Researchers discovered that abciximab significantly decreased heart muscle damage in ST-segment-elevation myocardial infarction patients. Clot aspiration did not show similar benefits.
Horst Sievert, a leading expert in non-coronary interventions, has advanced the field of interventional cardiovascular medicine through technical excellence. He has performed over 25,000 percutaneous coronary interventions and 12,000 peripheral angioplasties.
The PEPCAD-DES trial demonstrated paclitaxel-coated balloon angioplasty is more effective than plain old uncoated-balloon angioplasty in treating drug-eluting stent restenosis. The procedure resulted in lower late lumen loss, binary restenosis rates, and major adverse cardiac events.
The REMEDEE trial demonstrated that the new dual therapy stent effectively controls neointimal proliferation, with low rates of clinical events and comparable results to paclitaxel-eluting stents. The study showed non-inferiority compared to a clinically proven stent in ischemic heart disease patients.
The TWENTE trial demonstrated non-inferiority between zotarolimus- and everolimus-eluting stents, with low rates of target vessel failure and stent thrombosis. The study showed similar efficacy in a broad patient population with complex lesions and 'off-label' indications.
The ADVISE trial demonstrated that instantaneous wave-free ratio (iFR) is comparable to fractional flow reserve (FFR) without the use of adenosine. The study found excellent diagnostic efficiency and correlation between iFR and FFR, with potential clinical implications for improving patient experience and workflow in cath labs.
Researchers found that polymer-free amphilimus-eluting stents resulted in significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents. The trial, NEXT, demonstrated non-inferiority of these stents in de novo native coronary artery lesions.
A clinical trial testing rotational atherectomy prior to implantation of a drug-eluting stent found that the process was not superior to standard balloon angioplasty and decreased the efficacy of the stent. Rotablation followed by drug-eluting stenting is not supported by randomized studies in complex calcified lesions.
The EVOLVE trial found that a bioabsorbable polymer stent was non-inferior to traditional durable polymer stents in treating de novo coronary artery disease, with lower rates of late events and reduced need for dual antiplatelet therapy.
The PROFI trial found that proximal balloon occlusion resulted in fewer cerebral ischemic lesions compared to filter protection during carotid artery stenting. This reduction was associated with a lower risk of stroke and other major adverse cardiovascular events.
The COBRA trial found that cryoplasty post-dilation decreases the risk of in-stent restenosis by 26.5% compared to conventional balloon angioplasty in patients with diabetes. Researchers used a cryoplasty dilatation system that simultaneously dilates and cools the vessel wall, inducing smooth muscle cell apoptosis.
The DEB-AMI trial found that drug-eluting balloons with bare metal stents did not meet the primary endpoint of reduced late lumen loss compared to drug-eluting stents. The study also showed that these procedures may induce more pronounced morphological changes, resulting in inferior angiographical and clinical outcomes.
The PARTNER trial demonstrates continued superiority of TAVR over standard therapy at 2-year follow-up, with reduced rates of all cause mortality, cardiovascular mortality, and repeat hospitalization. Neurologic events were higher in TAVR patients, primarily due to increased hemorrhagic strokes.
A new analysis of the PARTNER trial found that TAVR via the femoral artery is more cost-effective than SAVR for eligible high-risk patients, while transapical approach yields unattractive results from a health economic perspective. The study suggests that refinement of the transapical approach could improve outcomes and reduce costs.
A study found that transcatheter aortic valve replacement (TAVR) provides meaningful clinical benefits compared to surgical valve replacement in patients suitable for the transfemoral approach. In contrast, patients ineligible for this approach experienced no benefit and potentially worse outcomes with TAVR.
The study found that radial artery access was associated with significantly lower rates of bleeding and cardiac death compared to femoral artery access. This suggests that the transradial approach may be a preferable option for patients with ST elevation acute coronary syndrome.
The STACCATO trial found that transapical transcatheter aortic valve implantation (a-TAVI) may be inferior to surgical aortic valve replacement (SAVR) in operable elderly patients, with a higher risk of death, stroke, and renal failure at 30 days. The study was terminated early due to safety concerns.
The BRIDGE trial shows cangrelor provides effective maintenance of platelet inhibition with no apparent increase in major bleeding, but numerically higher rates of minor bleeding prior to surgery. Researchers found the investigational drug cangrelor could serve as a 'bridge' between discontinuing thienopyridines and surgery.
Dr. Eric J. Topol was awarded the 2011 TCT Career Achievement Award for his groundbreaking research on acute myocardial infarction and interventional pharmacology, which has benefited millions of patients with cardiovascular disease. He is also a leader in personalized medicine and digital technology.
The HORIZONS-AMI trial found that bivalirudin reduces all-cause mortality and cardiac mortality by 18% compared to heparin plus a GP IIb/IIIa inhibitor. Drug-eluting stents also show lower rates of ischemia-driven target lesion revascularization with equivalent safety.
A new study published in the New England Journal of Medicine reveals that most untreated plaques causing unexpected heart attacks have large plaque burdens or small lumen areas, making them detectable by grayscale IVUS. The use of combination imaging modalities improves the ability to predict future adverse events.
Lillian Feldshuh, an early transcatheter aortic valve recipient, received the Courageous Patient Award at TCT 2010. She was successfully treated for life-threatening aortic stenosis and remains in good health.
A robotically assisted percutaneous coronary intervention system has been shown to be safe and feasible in a first-in-human study, reducing radiation exposure and contrast media usage. The technique allows for technical precision and improved procedural effectiveness compared to manual PCI.
A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at 6 months, according to a study led by Laura Mauri, MD. The bioresorbable polymer and stent design showed better clinical outcomes and reduced stent thrombosis risk without compromising anti-restenotic efficacy.
The LEADERS trial shows a biolimus A9-eluting stent with biodegradable polymer is non-inferior to a sirolimus-eluting stent with durable polymer in terms of safety and efficacy at 3 years. Researchers found that both stents have equivalent rates of target lesion revascularization, cardiac death, myocardial infarction, and clinically in...
The CREATE study demonstrated satisfactory angiographic and clinical outcomes for biodegradable polymer-based sirolimus eluting stents. The use of these stents with a recommended antiplatelet regimen resulted in a low rate of major adverse cardiac events and stent thrombosis.
A new percutaneous mitral valve clip device demonstrated significant clinical benefits for patients with mitral valve regurgitation, improving left ventricular function and quality of life scores. The study found that patients with reduced MR grade at 12 months experienced marked clinical benefit.
The study found that everolimus-eluting stents demonstrated enhanced safety and efficacy compared to paclitaxel-eluting stents in treating de novo native coronary artery lesions. The trial showed a significant reduction in target-lesion failure and ischemia-driven TLR rates with the use of everolimus-eluting stents.
The HORIZONS-AMI trial demonstrates that drug-eluting stents are safer and more effective than bare-metal stents for heart attack patients. Bivalirudin anticoagulation enhances safety and efficacy compared to heparin + GPIIb/IIIa inhibitors.
The PROSPECT trial reveals that most unexpected heart attacks are caused by large plaque burdens and small lumen areas, not mild lesions. Characterization of plaque composition using virtual histology improves the ability to predict future adverse events.
A recent clinical trial has found that the combination of clopidogrel and stomach medicines does not lead to adverse events. The COGENT trial involved 3,627 patients and showed a significant reduction in gastrointestinal events with PPI use.
The SPIRIT IV trial demonstrates enhanced safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents, resulting in a 38% reduction in target lesion failure (TLF) rate at one year. The study also found significant reductions in ischemia-driven TLR and stent thrombosis rates with the everolimus stent.
A multicenter study found drug-eluting stents to be effective in treating patients with chronic total occlusions, with low rates of major adverse cardiac events. The study also showed that certain drug-eluting stents, such as SES and EES, had a lesser rate of angiographic restenosis compared to others.
A new type of sirolimus-eluting stent successfully demonstrated greater neointimal suppression and vessel wall integrity compared to paclitaxel-eluting stents. This study, presented at the TCT scientific symposium, confirms the superiority of the sirolimus-eluting stent for treating coronary artery disease.
Researchers found exceptionally low rates of complications and stable gradient release after one-year follow-up. Multiple vascular access sites are feasible, but periprocedural complications are considerable due to the high-risk patient population.
A multicenter study found that drug-eluting stents are safe and effective in patients with diabetes, with low acute complications. The study showed a lower rate of restenosis for certain stent types, such as SES, BES, and EES.